Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Prof Lee Soo Chin

Designations:
  • Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Qualifications:
MBBS, MRCP (UK), M Med (Int Med), FAMS, FRCP (UK), Familial Cancer Risk Assessment and Management Credential (Institute for Clinical Evaluation, USA)
Specialties:
Medical Oncology
Sub-Specialties:
Cancer Genetics
Special Interests:
Breast cancer, Cancer genetics, Pharmacogenetics

Biosketch

Prof Lee obtained her medical degrees from the National University of Singapore and the Royal College of Physicians, United Kingdom, and completed a fellowship in cancer genetics at the Johns Hopkins School of Medicine, United States. She is currently Head and Senior Consultant with the Department of Haematology-Oncology, and Associate Director of Research at NCIS, as well as Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. 

She specialises in breast cancer and directs the Cancer Genetics program at NCIS. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute. 

She was awarded the Singapore National Medical Research Council Senior Clinician Scientist Award in 2009 and again in 2015, and has almost 150 peer-reviewed publications in major oncology and pharmacogenetics journals, including Cancer, Oncology, Lancet Oncology, JAMA Oncology, Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Clinical Pharmacology and Therapeutics, Pharmacogenetics and Genomics, Breast Cancer Research and Treatment, New England Journal of Medicine and Nature Genetics. She has reviewed for international journals including Gut, British Journal of Cancer, Pharmacogenetics and Genomics, Personalized Medicine, Annals of Oncology, Cancer Chemotherapy and Pharmacology, and Pharmacogenomics.

Awards

  • 2020 - National Day Awards - Long Service Medal
  • 2016 - National Medical Reserach Council Awards - Clinician Scientist Award Senior Investigator

Journals & Publications

  1. ​Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Wong AL, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Soh TI, Pang AS, Tan CS, Ow SG, Wang L, Mogro J, Ho J, Jeyasekharan AD, Huang Y, Thng CH, Chan CW, Hartman M, Iau P, Buhari SA, Goh BC, SC Lee. Oncotarget 2016; 7(39): 64089-99.
  2. High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Wang T, Srivastava S, Hartman M, Buhari SA, Chan CW, Iau P, Khin LW, Wong A, Tan SH, Goh BC, SC Lee. Oncotarget 2016; 7(34): 55155-68.
  3. Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment. Khoo BL, Grenci G, Jing T, Lim YB, SC Lee, Thiery JP, Han J, Lim CT. Sci Adv 2016; 2(7): e1600274.
  4. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomized, double-blind, placebo-controlled phase 2 trial. IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, B Melicha, A Forero-Torres, SC Lee, R de Boer, K Petrakova, S Vallentin, EA Perez, M Piccart, M Ellis, E Winer, S Gendreau, M Derynck, M LAckner, G Levy, J Qiu, J He, P Schmid. Lancet Oncol 2016; 17(6): 811-21.
  5. Phase Ib/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. A Kong, D Rea, S Ahmed, JT Beck, RL Lopez, L Biganzoli, AC Armstrong, M Aglietta, E Alba, M Campone, SH Schmitz, C Lefebvre, M Akomov, SC Lee. Oncotarget 2016 Apr 25 (epub ahead of print).
  6. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial. A Awada, R Colomer, K Ionue, I Bondarenko, RA Badwe, G Demetriou, SC Lee, AO Mehta, SB Kim, T Bachelot, C Goswami, S Deo, R Bose, A Wong, F Xu, B Yao, R Bryce, LA Carey. JAMA Oncol 2016, Apr 14 (epub ahead of print)
  7. Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. L Wang, DD Phan, J Zhang, PS Ong, WL Thuya, RA Soo, AL Wong, WP Yong, SC Lee, PC Ho, G Sethi, BC Goh. Oncotarget 2016, Mar 2014 (epub ahead of print).
  8. High throughput mutation profiling changes before and 3 weeks after chemotherapy in newly diagnosed breast cancer patients. SH Tan, NS Sapari, H Miao, M Hartman, M Loh, WJ Chng, P Iau, SA Buhari, R Soong, SC Lee. Plos One 2015, Dec 2; 10(12): e0142466.
  9. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signaling are reversed by metabolic products of the mevalonate pathway. TT Wang, S Seah, XY Loh, CW Chan, M Hartman, BC Goh, SC Lee. Oncotarget 2015, Nov 11 (epub ahead of print).
  10. Genetic factors affecting drug disposition in Asian cancer patients. NL Syn, WP Yong, SC Lee, BC Goh. Expert Opin Drug Metab Toxicol 2015, Dec ; 11(12): 1879-92.

Professional Memberships

  • Member, American Society of Clinical Oncology
  • Fellow and Past Chairperson, Chapter of Medical Oncologists, Academy of Medicine, Singapore Member, Singapore Society of Oncology


 

Back to Top